Xenon Pharmaceuticals Inc
XENE
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.42B
Close$
$2.34
93.4% downside
Current Fair Value
93.4% downsideOvervalued by 93.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.42 Billion |
|---|---|
| Enterprise Value | $3.31 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.36 |
| Beta | 0.6 |
| Outstanding Shares | 99,609,804 |
Return
| Return on Equity | -32.94% |
|---|---|
| Return on Assets | -31.58% |
| Return on Invested Capital | -33.96% |
Valuation & Multiples
| P/E Ratio | -7.46 |
|---|---|
| PEG | -24.26 |
| Price to Sales | - |
| Price to Book Ratio | 2.95 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.79 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-1.17
Average shareholder expectationRevenue Estimate
$1.50 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-1.13
Average shareholder expectationRevenue Estimate
$1.33 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 10.24% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.35%▼ 101.44% |
|---|---|
| Total Invested | $13.00M▼ 99.79% |
| Investors Holding | 22▼ 303.00% |
ESG Score
No data
About Xenon Pharmaceuticals Inc
CEO: Simon Pimstone